retatrutide ly3437943 clinical trial Results: 28.3% Weight Loss Data A Study of Retatrutide (LY3437943)

We sought to investigate the real-world impact of sodiumglucose cotransporter 2 inhibitor (SGLT2i) and glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in individuals with type 1 diabetes in relation to effect on blood glucose levels, adverse events and cardio-renal outcomes

In real-world settings multiple factors contribute to non-persistence, including adverse effects, high cost-sharing and weight loss not meeting patients' expectations.

Our San Francisco and Palo Alto physicians explore the potential positive effects of weight loss medications on sleep apnea patients

Stronger inverse associations were seen among older men (70 years) (ITT HR 0.56

Gallbladder removal changes how your body handles fats and bile acids, raising important questions about GLP-1 therapy safety

We connect you with top Semaglutide providers for effective weight loss treatment